Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Electrocore Inc (ECOR)

Electrocore Inc (ECOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,855
  • Shares Outstanding, K 6,003
  • Annual Sales, $ 16,030 K
  • Annual Income, $ -18,830 K
  • 60-Month Beta 0.91
  • Price/Sales 2.09
  • Price/Cash Flow N/A
  • Price/Book 4.44
Trade ECOR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.50
  • Number of Estimates 2
  • High Estimate -0.46
  • Low Estimate -0.54
  • Prior Year -1.24
  • Growth Rate Est. (year over year) +59.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.32 +6.20%
on 04/17/24
6.95 -18.71%
on 03/20/24
-1.28 (-18.47%)
since 03/19/24
3-Month
5.32 +6.20%
on 04/17/24
8.08 -30.07%
on 01/30/24
-0.98 (-14.78%)
since 01/19/24
52-Week
3.83 +47.58%
on 06/27/23
8.08 -30.07%
on 01/30/24
-1.17 (-17.16%)
since 04/19/23

Most Recent Stories

More News
Ecora Resources PLC Announces Q2 2023 Trading Update

Ecora Resources PLC ("Ecora", the "Group" or the "Company") Q2 2023 Trading Update

ECOR : 5.65 (+0.18%)
ECOR.LN : 82.800 (-1.19%)
ECOR.TO : 1.45 (-0.68%)
ECRAF : 1.0250 (+1.49%)
electroCore and Joerns Healthcare Partner to Expand Use Of gammaCoreâ„¢ Vagus Nerve Technology for Headache Sufferers

/PRNewswire/ -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage, bioelectronic medicine company, announced today that gammaCore Sapphireâ„¢, the first and...

ECOR : 5.65 (+0.18%)
electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference

ROCKAWAY, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced...

ECOR : 5.65 (+0.18%)
electroCore to Announce Second Quarter 2022 Financial Results on August 4

ROCKAWAY, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today...

ECOR : 5.65 (+0.18%)
electroCore Provides Select Second Quarter 2022 Financial Guidance

Record revenue will be at least $2.1 million; approximately 65% growth over second quarter 2021June 30, 2022, cash and cash equivalents balance of...

ECOR : 5.65 (+0.18%)
electroCore, Inc. Announces Study of gammaCore Sapphireâ„¢ for the Treatment of Post-COVID Syndrome

ROCKAWAY, N.J., July 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today...

ECOR : 5.65 (+0.18%)
electroCore, Inc. Announces gammaCoreâ„¢ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced...

ECOR : 5.65 (+0.18%)
electroCore to Participate at Upcoming Investor Conferences

ROCKAWAY, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced...

ECOR : 5.65 (+0.18%)
electroCore Announces Record First Quarter 2022 Financial Results

First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially Company to host a conference call and webcast...

ECOR : 5.65 (+0.18%)
electroCore Completes Sale of New Jersey Tax Benefits

ROCKAWAY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced...

ECOR : 5.65 (+0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

electroCore Inc. is a commercial-stage bioelectronic medicine company. Its current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache. electroCore Inc., formerly known as ELECTROCORE LLC, is based in LOS ANGELES, CA....

See More

Key Turning Points

3rd Resistance Point 6.80
2nd Resistance Point 6.57
1st Resistance Point 6.11
Last Price 5.65
1st Support Level 5.42
2nd Support Level 5.19
3rd Support Level 4.73

See More

52-Week High 8.08
Fibonacci 61.8% 6.46
Fibonacci 50% 5.95
Last Price 5.65
Fibonacci 38.2% 5.45
52-Week Low 3.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar